The aim of the current study was therefore to investigate the antimicrobial and antibiofilm activities of a range of bacteria including organisms isolated from human skin, and the candidate probiotic E. coli Nissle 1917. E. coli Nissle 1917 is a commonly studied candidate probiotic bacterium.

Aim of this study was to investigate QS of Escherichia coli Nissle 1917 (Mutaflor). Results: While E. coli Nissle is producing AI-2 in a density dependent manner, no AI-1 was produced. To study the effect of AI-2 in the DSS (dextran sulphate sodium) induced mouse model of acute colitis, we silenced the corresponding gene luxS by intron insertion. Escherichia coli (Nissle) Mutaflor: Now Foods Probiotic-10: Lactobacillus acidophilus, casei, delbrueckii subsp bulgaricus, paracasei, plantarum: Now Foods Probiotic-10: Escherichia coli (Nissle)
Escherichia coli strains are found as part of normal human gut microbiota. In this work, we elucidate the pathway that mediate internalization of OMVs from the probiotic E.coli Nissle 1917 (EcN) and the commensal ECOR12 strains in several human intestinal epithelial cell lines.
Here, we investigated whether OMVs from the probiotic Escherichia coli strain Nissle 1917 or the commensal E. coli strain ECOR12 trigger immune responses in various cellular models: (i) peripheral blood mononuclear cells (PBMCs) as a model of intestinal barrier disruption, (ii) apical stimulation of Caco-2/PMBCs co-culture as a model of intact The list of such microorganisms continues to grow and includes many strains of lactic acid bacilli (eg, Lactobacillus and Bifidobacterium), a nonpathogenic strain of Escherichia coli (eg, E. coli Nissle 1917), Clostridium butyricum, Streptococcus salivarius, and Saccharomyces boulardii (a nonpathogenic strain of yeast). A high carriage rate of multidrug-resistant Escherichia coli (MDREC) was observed in elderly residents in long-term care facilities. A double-blinded, placebo-controlled trial was carried out to determine whether the probiotic product E. coli strain Nissle 1917 (Mutaflor) would compete with MDREC in …
Abstract. A century ago, Alfred Nissle discovered that intentional intake of particular strains of Escherichia coli could treat patients suffering from infectious diseases. Since then, one of these strains became the most frequently used probiotic E. coli in research and was applied to a variety of human conditions.
Membrane vesicles (MVs) produced by Gram-negative bacteria are being explored for novel clinical applications due to their ability to deliver active molecules to distant host cells, where they can exert immunomodulatory properties. MVs released by the probiotic Escherichia coli Nissle 1917 (EcN) are good candidates for testing such applications. However, a drawback for such studies is the low One such example is the probiotic bacterium Escherichia coli Nissle 1917 (E. coli Nissle, or EcN), a strain that was first isolated in WWI from the stool of a soldier who did not develop An update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety is proposed, and the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine is proposed. Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors The most striking data exist for Escherichia coli strain Nissle 1917 (EcN) in the maintenance of remission of ulcerative colitis (17, 18, 33). Treatment with EcN demonstrated beneficial effects equal to those of mesalamine . However, the mechanisms by which EcN mediates its effects are not fully understood.
By administering Escherichia coli strain Nissle 1917, which assimilates iron by similar mechanisms, we show that this non-pathogenic bacterium can outcompete and reduce S. Typhimurium colonization in mouse models of acute colitis and chronic persistent infection. This probiotic activity depends on E. coli Nissle iron acquisition as mutants
Recently, we have found that hBD-2 induction by probiotic Escherichia coli Nissle 1917 was mediated through NF-κB- and AP-1-dependent pathways. The aim of the present study was to identify the responsible bacterial factor. E. coli Nissle 1917 culture supernatant was found to be more potent than the pellet, indicating a soluble or shed factor edYf.
  • 6w182m5kle.pages.dev/274
  • 6w182m5kle.pages.dev/519
  • 6w182m5kle.pages.dev/223
  • 6w182m5kle.pages.dev/371
  • 6w182m5kle.pages.dev/436
  • 6w182m5kle.pages.dev/155
  • 6w182m5kle.pages.dev/42
  • 6w182m5kle.pages.dev/251

    • escherichia coli nissle 1917 probiotic